News
By sparking the immune system into action, radiation therapy makes certain tumors that resist immunotherapy susceptible to ...
During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...
During a live event, Mark Yarchoan, MD, and participants discussed their impressions of the CheckMate-9DW trial data in ...
News-Medical.Net on MSN14h
Radiation primes the immune system to attack lung tumors resistant to immunotherapyBy sparking the immune system into action, radiation therapy makes certain tumors that resist immunotherapy susceptible to ...
The FDA’s decision to reject Replimune’s (NASDAQ:REPL) lead asset RP1 for a type of skin cancer known as melanoma appears to ...
Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...
HOLON, Israel I July 21, 2025 I Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive ...
Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...
IFLScience on MSN19h
Could We Be On Track Towards A Universal Cancer Vaccine? New Findings Say: MaybeA future “off the shelf” mRNA vaccine could boost existing treatments and provide a new option for resistant tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback